➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Johnson and Johnson
Baxter
Mallinckrodt
Boehringer Ingelheim

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GTS-21

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug GTS-21?

GTS-21 is an investigational drug.

There have been 8 clinical trials for GTS-21. The most recent clinical trial was a Phase 2 trial, which was initiated on June 16th 2018.

The most common disease conditions in clinical trials are Tourette Syndrome, Schizophrenia, and Syndrome. The leading clinical trial sponsors are CoMentis, University of Colorado, Denver, and National Institute of Mental Health (NIMH).

There are eighteen US patents protecting this investigational drug and one hundred and four international patents.

Recent Clinical Trials for GTS-21
TitleSponsorPhase
Selective Microbiota Transplantation for Tourette's SyndromeFaming ZhangPhase 1/Phase 2
Evaluating the Efficacy and Safety of Yi-Gan San in Children and Adolescents With Tourette's DisorderChina Medical University HospitalPhase 2
Effects of GTS-21 on Smoking Behavior and Neurocognitive FunctionsUniversity of FloridaPhase 2

See all GTS-21 clinical trials

Clinical Trial Summary for GTS-21

Top disease conditions for GTS-21
Top clinical trial sponsors for GTS-21

See all GTS-21 clinical trials

US Patents for GTS-21

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GTS-21   Start Trial Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists The Feinstein Institute for Medical Research (Manhasset, NY)   Start Trial
GTS-21   Start Trial Inhibition of inflammation using .alpha. 7 receptor-binding cholinergic agonists The Feinstein Institute for Medical Research (Manhasset, NY)   Start Trial
GTS-21   Start Trial Treatment of inflammation using .alpha.7 receptor-binding cholinergic agonists The Feinstein Institute for Medical Research (Manhasset, NY)   Start Trial
GTS-21   Start Trial Amide derivatives as positive allosteric modulators and methods of use thereof Abbott Laboratories (Abbott Park, IL)   Start Trial
GTS-21   Start Trial Amide derivatives as positive allosteric modulators and methods of use thereof Abbott Laboratories (Abbott Park, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GTS-21

Drugname Country Document Number Estimated Expiration Related US Patent
GTS-21 Austria 378048 2022-12-06   Start Trial
GTS-21 Australia 2003298939 2022-12-06   Start Trial
GTS-21 Canada 2507502 2022-12-06   Start Trial
GTS-21 China 102657651 2022-12-06   Start Trial
GTS-21 China 1735414 2022-12-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Johnson and Johnson
Baxter
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.